Impact of female hormones on blood pressure: Review of potential mechanisms and clinical studies

Current Hypertension Reports

Volumn 5, Issue 6, 2003, Pages 505-512

  Kotchen, Jane Morley ^a   Kotchen, Theodore A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYPROTERONE ACETATE; DEOXYCORTICOSTERONE ACETATE; DIETHYLSTILBESTROL; ESTRADIOL; ESTRAMUSTINE PHOSPHATE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MESTRANOL; NORADRENALIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE MODEL; DRUG MEGADOSE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INCIDENCE; NONHUMAN; POSTMENOPAUSE; PROSTATE CANCER; REVIEW; RISK FACTOR;

EID: 3142516293     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0059-0     Document Type: Review

References (78)

1. Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801-1811.
2. Gehard M, Walsh BW, Tawakol A, et al.: Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998, 98:1158-1163.
3. Wakatsuki A, Okatani Y, Ikenoue N, et al.: Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001, 104:1773-1778.
4. Zhang L, Kosake H: Sex-specific acute effect of estrogen on endothelium-derived contracting factor in the renal artery of hypertensive Dahl rats. J Hypertens 2002, 20:237-246.
5. Wassmann S, Laufs U, Stamenkovic D, et al.: Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhances nitric oxide production. Circulation 2002, 105:2083-2091.
6. White RE, Darkow DJ, Lang JL: Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res 1995, 77:936-942.
7. Oelkers WKH: Effects of estrogen and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996, 61:166-171.
8. He X, Wang W, Crofton J, et al.: Effect of 17 beta-estradiol on sympathetic activity and pressor response to phenylephrine in ovariectomized rats. J Appl Physiol 1998, 275:R1202-R1208.
9. Mohamed M, El-Mas M, Abdel-Rahman A: Estrogen enhancement of baroreflex sensitivity is centrally mediated. J Appl Physiol 1999, 276:R1030-R1037.
10. Minson CT, Halliwill JR, Young TM, et al.: Influence of the menstrual cycle on sympathetic activity, baroreflex sensitivity, and vascular transduction in young women. Circulation 2000, 101:862-868.
11. Hunt BE, Taylor A, Hamner JW, et al.: Estrogen replacement therapy improves baroreflex regulation of vascular sympathetic outflow in postmenopausal women. Circulation 2001, 103:2909-2914.
12. De Meersman RE, Zion AS, Giardina EGV, et al.: Estrogen replacement, vascular-distensibility, and blood pressure in postmenopausal women. Am J Physiol 1998, 274:H1539-H1544.
13. Huikuri H, Pikkujamsa S, Airksien J, et al.: Sex-related differences in autonomic modulation of heart rate in middle-aged subjects. Circulation 1996, 94:122-125.
14. Sudhir K, Esler M, Jennings G, et al.: Estrogen supplementation decreases norepinephrine-induced vasoconstriction and total body norepinephrine spillover in perimenopausal women. Hypertension 1997, 30:1538-1543.
15. Lindheim SR, Legro RS, Bernstein L, et al.: Behavioral stress responses in premenopausal and postmenopausal women and the effects of estrogen. Am J Obstet Gynecol 1992, 167:1831-1836.
16. Sung BH, Ching M, Izzo JL, et al.: Estrogen improves norepinephrine-induced vasoconstriction in postmenopausal women. J Hypertens 1999, 17:523-528.
17. Vongpatanasin W, Tuncel M, Mansour Y, et al.: Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation 2001, 103:2903-2908.
18. Weitz G, Elam M, Born J, et al.: Postmenopausal estrogen administration suppresses muscle sympathetic nerve activity. J Clin Endocrinol Metab 2001, 86:344-348.
19. Schunkert H, Danser AHJ, Hense H-W, et al.: Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997, 95:39-45.
20. Bridget BK, Weddle D, Anthony MS, et al.: Effect of chronic hormone replacement on the renin-angiotensin system in cynomolgus monkeys. J Hypertens 1997, 15:719-726.
21. Nickenig G, Baumer A, Anselm T, et al.: Estrogen modulates AT1 receptor gene expression in vitro and vivo. Circulation 1998, 97:2197-2201.
22. Dubey RK, Oparil S, Imthum B, et al.: Sex hormones and hypertension. Cardiovasc Res 2002, 53:688-708.
23. Fang Z, Carlson SH, Chen YF, et al.: Estrogen depletion induces NaCl-sensitive hypertension in female spontaneously hypertensive rats. Am J Physiol 2001, 281:R1934-R1939.
24. Roberts CK, Vaziri ND, Barnard RJ: Protective effects of estrogen on gender-specific development of diet-induced hypertension. J Appl Physiol 2001, 91:2005-2009.
25. Virdis A, Ghiadoni L, Pinto S, et al.: Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation 2000, 101:2258-2263.
26. Shiverick KT, Notelovitz M: Mestranol-induced hypertension; characterization of cytochrome P-450 dependent catechol estrogen formation in brain microsomes. Biochem Pharmacol 1983, 32:101-106.
27. Fortepiani LA, Zhang H, Racusen L, et al.: Characterization of an animal model of postmenopausal hypertension in spontaneously hypertensive rates. Hypertension 2003, 41:640-645.
28. Chan NM, MacAllister RJ, Colhoun HM, et al.: Changes in endothelium-dependent vasodilatation and α-adrenergic responses in resistance vessels during the menstrual cycle in healthy women. J Clin Endocrinol Metab 2001, 86:2499-2504.
29. Reckelhoff JF: Gender differences in the regulation of blood pressure. Hypertension 2001, 37:1199-1208.
30. Kotchen JM, Kotchen TA, Humphrey R, et al.: Hypertension detection and control in a rural white Kentucky community. Am J Public Health 1976, 66:79-81.
31. Heller RF, Jacobs HS: Coronary heart disease in relation to age, sex, and the menopause. BMJ 1978, 1:472-474.
32. Hjortland MC, McNamara PM, Kannel WB: Some atherogenic concomitants of menopause: the Framingham Study. Am J Epidemiol 1976, 103:304-311.
33. Mathews KA, Meilahn E, Kuller LH, et al.: Menopause and risk factors for coronary heart disease. N Engl J Med 1989, 321:641-646.
34. Laragh JH, Sealy JE, Ledingham JCG, Newton MA: Oral contraceptives, renin, aldosterone and high blood pressure. JAMA 1967, 201:918-922.
35. Crane MG, Harris JJ, Winsor W: Hypertension, oral contraceptive agents, and conjugated estrogens. Ann Intern Med 1971, 74:13-21.
36. Weir RJ, Briggs E, Mack A, et al.: Blood pressure in women after one year of oral contraception. Lancet 1971, 1:467-471.
37. Weir RJ, Briggs E, Mack A, et al.: Blood pressure in women taking oral contraceptives. BMJ 1974, 1:533-535.
38. Fisch IR, Frank J: Oral contraceptives and blood pressure. JAMA 1977, 237:2499-2503.
39. Kotchen JM, Kotchen TA, Cottrill CM, et al.: Blood pressures in young mothers and their first children 3-6 years following hypertension during pregnancy. J Chron Dis 1979, 32:653-659
40. Khaw K-T, Peart WS: Blood pressure and contraceptive use. BMJ 1982, 285:403-407.
41. Meade TW, Haines AP, North WRS, et al.: Hæmostatic, lipid, and blood pressure profiles of women on oral contraceptives containing 50 mg or 30 mg estrogen. Lancet 1977, 2:948-951.
42. Hubert HB, Faker ED, Garrison RJ, Castelli WP: Life-style correlates of risk factor change in young adults: an eight-year study of coronary heart disease risk factors in the Framingham offspring. Am J Epidemiol 1987, 125:812-831.
43. Wilson ESB, Cruickshank J, McMaster M, Weir RJ: A prospective controlled study of the effect of blood pressure of contraceptive preparations containing different types and dosage of progestogen. Br J Obstet Gyaecol 1984, 91:1254-1260.
44. Cairns V, Keil U, Doering A, et al.: Oral contraceptive use and blood pressure in a German metropolitan population. Internation J Epidemiol 1985, 14:389-395.
45. Baird DR, Glasier AF: Hormonal contraception. N Engl J Med 1993, 328:1543-1549.
46. Spellacy WN, Birk SA: The effect of intrauterine devices oral contraceptives, estrogens, and progestogens on blood pressure. Am J Obstet Gynecol 1972, 112:912-919.
47. Kay C: Oral contraceptives and health - some recent observations. In International Symposium on Hormonal Contraception. Proceedings of a symposium held in Utrecht, The Netherlands, September 1977. Edited by Haspels AA, Kay CR. Amsterdam-Oxford: Excerpta Medica; 1978:3-10.
48. Heintz B, Schmauder C, Witte K, et al.: Blood pressure rhythm and endocrine functions in normotensive women on oral contraceptives. J Hypertension 1996, 14:333-339.
49. Chasan-Taber L, Willet WC, Manson JE, et al.: Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996, 94:483-489.
50. Blumenstein BA, Douglas MB, Hall WD: Blood pressure changes and oral contraceptive use: a study of 2676 black women in the southeastern United States. Am J Epidemiol 1980, 112:539-552.
51. Coditz GA for The Nurses' Health Study Research Group: Oral contraceptive use and mortality during 12 years of follow-up: The Nurses' Health Study. Ann Intern Med 1994, 120:821-826.
52. Keating NL, Cleary PD, Rossi AS, et al.: Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999, 130:545-553.
53. Austin PC, Mamdani MM, Tu K, Jaakkimainen L: Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study [research letter]. JAMA 2003, 289:3241-3242.
54. Writing Group for the Women's Health Initiative: Risks and benefits of estrogen plus progestin in health postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
55. Lobo RA: Cardiovascular effects of estrogen deprivation. Proceedings of a symposium on the long-term effects of estrogen deprivation. Post Grad Med (Suppl) 1987, 82:29-30.
56. Mosca L, Collins P, Herrington DM, et al.: Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Assocation. Circulation 2001, 104:499-503.
57. Rodstrom K, Bengtsson C, Lissner L, Bjorkelund C: Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden. BMJ 1999, 319:890-893.
58. Cushman M, Meilahn EN, Psaty BM, et al.: Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999, 19:893-899.
59. Manolio TA, Furberg CD, Shemanski L, et al.: Progression of coronary artery disease: associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation 1993, 88:2163-2171.
60. Bush TL, Barrett-Conner E, Cowan LD, et al.: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987, 75:1102-1109.
61. Wilson PWF, Garrison RJ, Castelli WP: Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med 1985, 313:1038-1043.
62. Scuteri A, Bos AJG, Brant LJ, et al.: Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med 2001, 135:229-238.
63. Barrett-Connor E, Brown WV, Turner J, et al.: Heart disease risk factors and hormone use in postmenopausal women. JAMA 1979, 241:2167-2169.
64. Barrett-Connor E, Wingard DL, Criqui MH: Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, California, revisited. JAMA 1989, 261:2095-2100.
65. Stampfer MJ, Colditz; CA, Willett WC, et al.: Postmenopausal estrogen therapy and cardiovascular disease: ten year follow-up from the Nurses' Health Study. N Engl J Med 1991, 325:756-762.
66. The Writing Group for the PEPI Trial: Effects of estrogen and estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995, 273:199-208.
67. Angerer P, Störk S, Kothny W, et al.: Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001, 21:262-268.
68. Superko HR: Drug therapy and the prevention of atherosclerosis in humans. Am J Cardiol 1989, 64:31G-38G.
69. Byar DP, Corle DK: Hormone therapy for prostate cancer: results of the Veteran Administration Cooperative Urological Research Group Studies. NCI Monographs 1988, 7:165-170.
70. deVoogt HJ, Smith PH, Pavone-Macaluso M, et al.: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate, and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762. J Urol 1986, 135:303-307.
71. Blyth B, McRae CU, Espiner EA, et al.: Effect of stilboestrol on sodium balance, cardiac state, and renin-angiotensin-aldosterone activity in prostatic carcinoma. BMJ 1985, 291:1461-1464.
72. Komesaroff PA, Fullerton M, Esler MD, et al.: Low-dose estrogen supplementation improves vascular function in hypogonadal men. Hypertension 2001, 38:1011-1016.
73. Komesaroff PA, Fullerton M, Esler MD, et al.: Oestrogen supplementation attenuates responses to psychological stress in elderly men rendered hypogonadal after treatment for prostate cancer. Clin Endocrinol 2002, 56:745-753.
74. Del Rio G, Velardo A, Zizzo G, et al.: Effect of estradiol on the sympathoadrenal response to mental stress in normal men. J Clin Endocrinol Metab 1994, 79:836-840.
75. Slater AJ, Gude N, Clarke IJ, Walters WA: Haemodynamic changes and left ventricular performance during high-dose oestrogen administration to male transsexuals. Br J Obstet Gynaecol 1986, 93:532-538.
76. New G, Berry KL, Cameron JD, et al.: Long-term oestrogen treatment does not alter systemic arterial compliance and haemodynamics in biological males. Coron Artery Dis 2000, 11:253-259.
77. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER): Combined oral contraceptives: labeling for healthcare providers and patients. Rockville, MD: June 2000.
78. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER): Estrogen and estrogen/progestin drum products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms: recommendations for clinical evaluation. Rockville, MD: January 2003.